Equities

Orchid Pharma Ltd

ORCHPHARMA:NSI

Orchid Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,499.35
  • Today's Change-9.95 / -0.66%
  • Shares traded50.17k
  • 1 Year change+180.17%
  • Beta3.1933
Data delayed at least 15 minutes, as of Nov 08 2024 10:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments2,71130881
Total Receivables, Net1,9722,1612,231
Total Inventory2,6422,2871,727
Prepaid expenses------
Other current assets, total583253460
Total current assets7,9085,0104,499
Property, plant & equipment, net6,3606,1925,931
Goodwill, net------
Intangibles, net1493.863.37
Long term investments518513503
Note receivable - long term------
Other long term assets604533169
Total assets15,53912,25211,106
LIABILITIES
Accounts payable2,2961,8181,677
Accrued expenses------
Notes payable/short-term debt1401,410228
Current portion long-term debt/capital leases3.33416369
Other current liabilities, total16076133
Total current liabilities2,6003,7192,408
Total long term debt1,2081,4882,082
Total debt1,3523,3132,680
Deferred income tax--3232
Minority interest------
Other liabilities, total36126110
Total liabilities3,8445,3664,632
SHAREHOLDERS EQUITY
Common stock507408408
Additional paid-in capital------
Retained earnings (accumulated deficit)11,1876,4786,066
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity11,6956,8866,474
Total liabilities & shareholders' equity15,53912,25211,106
Total common shares outstanding514141
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.